Equivalent doses for anticancer agents used in pediatric oncology: A literature review and evaluation of a novel approach for conversion factors.
chemotherapeutics
childhood cancer
conversion factors
doses
second tumor
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
27
01
2023
received:
19
10
2022
accepted:
24
02
2023
medline:
12
5
2023
pubmed:
29
3
2023
entrez:
28
3
2023
Statut:
ppublish
Résumé
Epidemiological research on late effects of therapy shows the necessity to aggregate chemotherapy agents to substance classes. This requires using conversion factors by substance classes. The aim of this study was to identify previously used conversion factors from the literature, to present a novel approach for additional factors, and to compare these approaches. A literature review was performed, which identified two main principles of deriving conversion factors: effect-equivalence and equimolar. Thirty-five articles presenting effect equivalence-based factors in the widest sense were found in the literature. Ten articles presented the equimolar approach which can be applied to almost all chemotherapy substances. Based on a comprehensive list of treatment protocols used in German pediatric oncology, we derived alternative conversion factors from typical doses. We compared the conversion factors using Pearson correlation coefficients and linear regression. At least two types of conversion factor were available for each of the 49 substances included. The equivalent effect-based and the typical dose-based factors were highly correlated with a regression coefficient close to 1. The equimolar factors are independent. For substances for which no conversion factor based on some type of effect equivalence has been published so far, a factor based on a typical doses-approach may be used in epidemiological late effects research. Doses aggregated based on the equimolar approach may not be compatible with doses aggregated based on equivalent effects.
Sections du résumé
BACKGROUND
Epidemiological research on late effects of therapy shows the necessity to aggregate chemotherapy agents to substance classes. This requires using conversion factors by substance classes.
AIMS
The aim of this study was to identify previously used conversion factors from the literature, to present a novel approach for additional factors, and to compare these approaches.
METHODS AND RESULTS
A literature review was performed, which identified two main principles of deriving conversion factors: effect-equivalence and equimolar. Thirty-five articles presenting effect equivalence-based factors in the widest sense were found in the literature. Ten articles presented the equimolar approach which can be applied to almost all chemotherapy substances. Based on a comprehensive list of treatment protocols used in German pediatric oncology, we derived alternative conversion factors from typical doses. We compared the conversion factors using Pearson correlation coefficients and linear regression. At least two types of conversion factor were available for each of the 49 substances included. The equivalent effect-based and the typical dose-based factors were highly correlated with a regression coefficient close to 1. The equimolar factors are independent.
CONCLUSIONS
For substances for which no conversion factor based on some type of effect equivalence has been published so far, a factor based on a typical doses-approach may be used in epidemiological late effects research. Doses aggregated based on the equimolar approach may not be compatible with doses aggregated based on equivalent effects.
Identifiants
pubmed: 36975206
doi: 10.1002/cnr2.1811
pmc: PMC10172172
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1811Informations de copyright
© 2023 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
Lancet. 2003 May 31;361(9372):1881-93
pubmed: 12788587
Ann Intern Med. 2016 Jan 19;164(2):93-101
pubmed: 26747086
Drug Saf. 2000 Apr;22(4):263-302
pubmed: 10789823
J Clin Oncol. 2012 May 1;30(13):1415-21
pubmed: 22124095
J Clin Oncol. 2003 Mar 15;21(6):1074-81
pubmed: 12637473
Eur J Cancer. 2006 Nov;42(16):2757-64
pubmed: 16965909
Cancer Treat Rev. 1993 Jul;19(3):197-228
pubmed: 8334677
J Clin Endocrinol Metab. 2006 Oct;91(10):3954-61
pubmed: 16895963
Int J Clin Pharmacol Ther Toxicol. 1989 May;27(5):217-21
pubmed: 2737789
Leuk Lymphoma. 1999 Aug;34(5-6):415-32
pubmed: 10492065
Acta Oncol. 1990;29(3):343-7
pubmed: 2194535
J Endocrinol Invest. 1999 Dec;22(11):857-9
pubmed: 10710274
Blood. 1991 Apr 15;77(8):1666-74
pubmed: 2015395
Drugs. 1991 Oct;42(4):690-719
pubmed: 1723369
Acta Paediatr Suppl. 1993 Mar;388:56-60; discussion 61
pubmed: 8329832
Br J Haematol. 1998 Oct;103(1):100-9
pubmed: 9792296
J Clin Oncol. 2015 Nov 10;33(32):3774-80
pubmed: 26304888
J Endocrinol Invest. 2021 Apr;44(4):865-872
pubmed: 32779106
Blood. 2003 May 15;101(10):3809-17
pubmed: 12531809
Pediatr Blood Cancer. 2014 Jan;61(1):53-67
pubmed: 23940101
J Clin Oncol. 2005 Jan 1;23(1):197-204
pubmed: 15625374
Cancer. 1985 Jun 15;55(12):2761-5
pubmed: 3922612
Eur J Cancer. 2003 Nov;39(16):2379-86
pubmed: 14556931
Pediatr Blood Cancer. 2013 Oct;60(10):1574-81
pubmed: 23737479
Int J Cancer. 1998 Jul 29;77(3):370-7
pubmed: 9663598
BMJ. 2009 Dec 08;339:b4606
pubmed: 19996459
Pediatr Hematol Oncol. 2016 Sep;33(6):371-382
pubmed: 27687523
Clin Endocrinol (Oxf). 2003 Nov;59(5):613-20
pubmed: 14616886
BMJ. 2016 Sep 07;354:i4567
pubmed: 27604249
BMC Med Res Methodol. 2018 Nov 19;18(1):143
pubmed: 30453902
Unfallchirurg. 1992 Jun;95(6):284-7
pubmed: 1636106
Int J Cancer. 1998 Oct 29;78(3):269-75
pubmed: 9766556
BMJ Open. 2022 Nov 7;12(11):e065910
pubmed: 36344003
Cancer. 2003 Apr 15;97(8):1991-8
pubmed: 12673729
Cancer Treat Rev. 1985 Sep;12 Suppl A:59-65
pubmed: 3910223
Pediatr Blood Cancer. 2007 Jun 15;48(7):651-62
pubmed: 17183582
Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):e209-15
pubmed: 22672756
Ann Intern Med. 2018 Oct 2;169(7):467-473
pubmed: 30178033
Leukemia. 2000 Feb;14(2):340-2
pubmed: 10673757
J Endocrinol Invest. 2006 Sep;29(8):727-31
pubmed: 17033262
Cancer Rep (Hoboken). 2023 May;6(5):e1811
pubmed: 36975206
J Clin Oncol. 1993 Feb;11(2):209-17
pubmed: 8426196
Blood Adv. 2019 Nov 26;3(22):3688-3699
pubmed: 31765480
Med Pediatr Oncol. 1996 Dec;27(6):505-14
pubmed: 8888809
Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):224-30
pubmed: 22795729
Br J Cancer. 1999 Apr;79(11-12):1884-93
pubmed: 10206309
Int J Cancer. 2021 May 1;148(9):2079-2089
pubmed: 33105035
Blood. 1992 Jan 15;79(2):313-9
pubmed: 1730080
JAMA Oncol. 2019 Jun 01;5(6):864-871
pubmed: 30703192
Bone Marrow Transplant. 2000 Jul;26(2):187-92
pubmed: 10918429
Acta Oncol. 2006;45(4):438-48
pubmed: 16760180
J Endocr Soc. 2020 Oct 29;4(12):bvaa160
pubmed: 33241171
Lancet. 1997 Jul 12;350(9071):91-5
pubmed: 9228960
J Natl Cancer Inst. 1987 Mar;78(3):459-64
pubmed: 3469460
Pediatr Blood Cancer. 2004 Jun;42(7):556-62
pubmed: 15127409
Int J Cancer. 2007 Jan 1;120(1):96-102
pubmed: 17013899
Int J Cancer. 2004 May 20;110(1):87-93
pubmed: 15054872
Hemasphere. 2021 Jan 12;5(2):e518
pubmed: 33458594